epirubicin has been researched along with palonosetron in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Trissel, LA; Zhang, Y | 1 |
| Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E | 1 |
| Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y | 1 |
| An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z | 1 |
| Gourd, E | 1 |
| Araz, M; Artac, M; Beypinar, I; Inci, F; Karaagac, M; Koral, L; Korkmaz, L; Uysal, M | 1 |
| Iseki, K; Kobayashi, M; Nakai, M; Ogawa, K; Saito, Y; Sakamoto, T; Sugawara, M; Takekuma, Y; Yamada, T | 1 |
| Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K | 1 |
1 review(s) available for epirubicin and palonosetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for epirubicin and palonosetron
| Article | Year |
|---|---|
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Electric Stimulation Therapy; Epirubicin; Humans; Ifosfamide; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting; Young Adult | 2014 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Thalidomide; Vomiting; Young Adult | 2017 |
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Middle Aged; Morpholines; Nausea; Palonosetron; Patient Reported Outcome Measures; Vomiting | 2020 |
6 other study(ies) available for epirubicin and palonosetron
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Topics: Drug Interactions; Drug Stability; Epirubicin; Isoquinolines; Nephelometry and Turbidimetry; Palonosetron; Quinuclidines | 2005 |
Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Isoquinolines; Middle Aged; Nausea; Neoplasm Staging; Palonosetron; Prognosis; Quinuclidines; Serotonin Antagonists; Vomiting | 2013 |
Thalidomide reduces chemotherapy-induced vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Epirubicin; Humans; Isoquinolines; Palonosetron; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome; Vomiting | 2017 |
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Granisetron; Humans; Middle Aged; Nausea; Palonosetron; Prospective Studies; Vomiting | 2019 |
Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin.
Topics: Abdominal Pain; Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dexamethasone; Epirubicin; Female; Gastrointestinal Diseases; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Retrospective Studies; Vomiting | 2020 |